Artwork
iconShare
 
Manage episode 487021034 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE in patients with RA treated with JAKis compared to bDMARDs from the “JAK-pot” study, and the efficacy and safety of zimlovisertib, ritlecitinib and tofacitinib, alone and in combination, in patients with RA and an inadequate response to MTX.
  continue reading

385 episodes